Tubize-Fin Total Liabilities
Tubize-Fin total liabilities. Based on the latest financial reports, Tubize-Fin (TUB) has total liabilities worth €360.34K EUR (≈ $421.28K USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check TUB asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Tubize-Fin (2000–2025)
Total liabilities of Tubize-Fin from 2000 to 2025. This chart illustrates how Tubize-Fin's total liabilities have evolved over time, based on quarterly financial data. Explore TUB long-term investments to assets to see how much of total assets are deployed in long-term investments.
Tubize-Fin Competitors by Total Liabilities
The table below lists competitors of Tubize-Fin ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Companhia Paranaense de Energia - COPEL
NYSE:ELPC
|
USA | $37.71 Billion |
|
MOL NA A ADR REG.S 1/2
F:MOGG
|
Germany | €3.63 Trillion |
|
Berry Global Group Inc
NYSE:BERY
|
USA | $10.41 Billion |
|
Azek Company Inc
NYSE:AZEK
|
USA | $845.08 Million |
|
Impala Platinum Holdings Ltd
JSE:IMP
|
South Africa | ZAC39.24 Billion |
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr2.73 Billion |
|
Guangzhou Tinci Materials Technology Co Ltd
SHE:002709
|
China | CN¥11.61 Billion |
|
National Retail Properties Inc
NYSE:NNN
|
USA | $4.97 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Tubize-Fin's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Tubize-Fin assets under control.
Liquidity & Leverage Metrics
Tubize-Fin Total Liabilities Ratios Explained
Tubize-Fin total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 141.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.00 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tubize-Fin's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tubize-Fin (2000–2025)
The table below shows the annual total liabilities of Tubize-Fin from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €48.58 Million ≈ $56.79 Million |
-45.59% |
| 2024-12-31 | €89.28 Million ≈ $104.37 Million |
-27.80% |
| 2023-12-31 | €123.65 Million ≈ $144.56 Million |
+41.82% |
| 2022-12-31 | €87.19 Million ≈ $101.93 Million |
+316.40% |
| 2021-12-31 | €20.94 Million ≈ $24.48 Million |
-38.88% |
| 2020-12-31 | €34.26 Million ≈ $40.05 Million |
-60.83% |
| 2019-12-31 | €87.46 Million ≈ $102.25 Million |
-39.28% |
| 2018-12-31 | €144.04 Million ≈ $168.40 Million |
-26.38% |
| 2017-12-31 | €195.65 Million ≈ $228.74 Million |
-26.24% |
| 2016-12-31 | €265.26 Million ≈ $310.12 Million |
-14.94% |
| 2015-12-31 | €311.84 Million ≈ $364.57 Million |
+46.03% |
| 2014-12-31 | €213.55 Million ≈ $249.66 Million |
-15.67% |
| 2013-12-31 | €253.23 Million ≈ $296.05 Million |
-13.73% |
| 2012-12-31 | €293.53 Million ≈ $343.17 Million |
-8.36% |
| 2011-12-31 | €320.31 Million ≈ $374.48 Million |
-6.06% |
| 2010-12-31 | €340.97 Million ≈ $398.63 Million |
-7.00% |
| 2009-12-31 | €366.64 Million ≈ $428.64 Million |
-5.97% |
| 2008-12-31 | €389.92 Million ≈ $455.86 Million |
-5.77% |
| 2007-12-31 | €413.79 Million ≈ $483.77 Million |
+72.19% |
| 2006-12-31 | €240.31 Million ≈ $280.95 Million |
+104.48% |
| 2005-12-31 | €117.52 Million ≈ $137.40 Million |
-4.22% |
| 2004-12-31 | €122.70 Million ≈ $143.44 Million |
-21.41% |
| 2003-12-31 | €156.12 Million ≈ $182.52 Million |
-8.94% |
| 2002-12-31 | €171.45 Million ≈ $200.44 Million |
+33.07% |
| 2001-12-31 | €128.84 Million ≈ $150.63 Million |
+57.37% |
| 2000-12-31 | €81.87 Million ≈ $95.72 Million |
-- |
About Tubize-Fin
Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.